MedTrace Logo

Secondary Care - Continuous Glucose Monitoring

NCT03487887 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2022-09-13

No results posted yet for this study

Summary

Introduction and objective: The current state of glucose monitoring includes the use of A1C, self-monitoring of blood glucose (SMBG), and continuous glucose monitoring (CGM). CGM technology has got the potential to revolutionize diabetes care in the near future striving to optimal diabetes management and tight glucose control. Until very recently, this determination could only be achieved by the attainment of multiple capillary blood glucose determinations each day and/or measuring hemoglobin A1C. Those methods are not accurate in cases of unrecognized hypoglycemia, unrecognized nighttime events or in cases of large swings in blood glucose. Our aim is to analyze the benefit of tracking patterns of glucose values by using professional CGM technology used for "blinded" collection of glucose data retrospectively in patients with T2DM in secondary care- diabetologist clinic.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DEVICE

continuous glucose monitoring (CGM) iPro™2 Medtronic

A CGM device is to be set and take off by the diabetologist. Before the study start all diabetologist not familiar to the method will have a short education on CGM device. Study period is seven days and includes screening before study entry and two visits. On Day 1, after screening and signing the informed consent, the CGM device is applied. Patient is instructed to keep a 7 day diary with four daily standard SMBG along with the data on eating, physical exercise, drugs. On Day 7, CGM device is taken off and the data from iPro2 is uploaded to PC. At the end, each patient fills a short query on satisfaction while wearing CGM.

Sponsors & Collaborators

  • Takeda

    collaborator INDUSTRY

  • Croatian Society for Endocrinology and Diabology

    lead OTHER

Eligibility

Min Age
3 Days
Max Age
8 Days
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-19
Primary Completion
2021-08-25
Completion
2021-08-25

Countries

  • Croatia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03487887 on ClinicalTrials.gov